NIAID Preclinical Services Facilitate SARS-CoV-2 Vaccine Product Development by Standardizing the Microneutralization Assay for Phase III Vaccine Trials
Janet Lathey, Ph.D.
Program Officer, Office of Biodefense, Research Resources, and Translational Research, DMID/NIAID/NIH
